Article
Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
Expert opinion on therapeutic patents - 1 Dec 2016
Elbitar Sandy, Khoury Petra El, Ghaleb Youmna, Rabès Jean-Pierre, Varret Mathilde, Seidah Nabil G, Boileau Catherine, Abifadel Marianne
Abstract excerpt
INTRODUCTION: The identification by Abifadel et al. in 2003 of the first mutations of PCSK9 was the major breakthrough in the cholesterol field that led to a new therapeutic target. This discovery paved the way to new lipid lowering drugs reducing LDL-cholesterol levels through the inhibition of PCSK9. Two anti-PCSK9 monoclonal antibodies have received FDA and EMA approvals: Alirocumab and Evolocumab. Areas...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.